Atlas Trials

Analysis of the Role of Hepatocyte SLAMF3 Receptor and Drug Resistance Proteins (MDR) in Resistance to Treatment With Sorafenib in CHC Patients

Clinical trial NCT03113604 · WITHDRAWN

Trial details

NCT number
NCT03113604
Sponsor
Centre Hospitalier Universitaire, Amiens
Status
WITHDRAWN
Study type
OBSERVATIONAL
Hepatocyte ReceptorHepatocellular Carcinoma
Start date
2015-11-20
Primary completion
2016-11-20
Enrollment
0

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.